An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent
Liver cancer is a kind of high mortality cancer due to the difficulty of early diagnosis. It is necessary to develop the anticancer agents to treat liver cancer. Here, a novel chalcone derivative was synthesized and evaluated for anticancer activity in vitro against liver cancer cell lines (HepG2, SNU-423, SMMC7221, and SNU-398). The chalcone hybrid 9 displayed the antiproliferative effect against HepG2, SNU-423, SMMC7221 and SNU-398 cells with IC50 values of 0.9 μM, 2.7 μM, 6.2 μM and 4.6 μM, respectively. Cellular mechanisms showed that derivative 9 could obviously inhibit HepG2 cells growth and colony formation in a concentration-dependent manner. Analogue 9 inhibited the migration by regulating the expression levels of migration-releated markers and transcription factors (Snail and Slug). Tubulin polymerization inhibition assay illustrated that chalcone hybrid 9 might be a potent tubulin polymerization inhibitor. Importantly, compound 9 displayed the antitumor activity against liver cancer HepG2 cells in vivo with the low toxicity toward mice. Therefore, compound 9 as a novel tubulin polymerization inhibitor deserves further investigation to treat liver cancer.
KeywordsChalcone Liver cancer Cell growth Migration Tubulin
So thanks the supports from The First Affiliated Hospital of Zhengzhou University.
Wang Yan., Chen Xiangyu., Li Ya., and Wang Yu. performed the design work and experiments. Wang Yan., and Xu Feng. witten the paper. All authors read and approved the final manuscript.
This work was supported by the fund of The First Affiliated Hospital of Zhengzhou University.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 1.Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang DCL, Schnell D, Hocke J, Loembé AB, Cheng AL (2018) A phase I/randomized phase II study to evaluate the safety, pharmacokinetics, and efficacy of Nintedanib versus Sorafenib in Asian patients with advanced hepatocellular carcinoma. Liver Cancer 7(2):165–178CrossRefGoogle Scholar
- 3.Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM (2015) Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investig New Drugs 33(4):911–920. https://doi.org/10.1007/s10637-015-0251-5 CrossRefGoogle Scholar
- 15.Kakwani MD, Suryavanshi P, Ray M, Rajan MGR, Majee S, Samad A, Devarajan P, Degani MS (2011) Design, synthesis and antimycobacterial activity of cinnamide derivatives: a molecular hybridization approach. Bioorg Med Chem Lett 21(7):1997–1999. https://doi.org/10.1016/j.bmcl.2011.02.022 CrossRefGoogle Scholar
- 16.Barbosa TP, Sousa SCO, Amorim FM, Rodrigues YKS, de Assis PAC, Caldas JPA, Oliveira MR, Vasconcellos MLAA (2011) Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach. Bioorg Med Chem 19(14):4250–4256. https://doi.org/10.1016/j.bmc.2011.05.055 CrossRefGoogle Scholar
- 20.Özdemir A, Sever B, Altıntop M, Kaya Tilki E, Dikmen M (2018) Design, synthesis, and neuroprotective effects of a series of Pyrazolines against 6-hydroxydopamine-induced oxidative stress. Molecules 23(9). https://doi.org/10.3390/molecules23092151
- 21.Rampa A, Bartolini M, Pruccoli L, Naldi M, Iriepa I, Moraleda I, Belluti F, Gobbi S, Tarozzi A, Bisi A (2018) Exploiting the Chalcone scaffold to develop multifunctional agents for Alzheimer’s disease. Molecules 23(8). https://doi.org/10.3390/molecules23081902
- 22.Teng IJ, Tsai M-C, Shih S-F, Tsuei B-F, Chang H, Chuang Y-P, Lin C-S, Chern C-Y, Chen S-J (2018) Chalcone derivatives enhance ATP-binding cassette transporters A1 in human THP-1 macrophages. Molecules 23(7). https://doi.org/10.3390/molecules23071620
- 23.Huang X, Shen Q-K, Zhang H-J, Li J-L, Tian Y-S, Quan Z-S (2018) Design and synthesis of novel Dehydroepiandrosterone analogues as potent Antiproliferative agents. Molecules 23(9). https://doi.org/10.3390/molecules23092243
- 24.Kamal A, Shankaraiah N, Devaiah V, Laxma Reddy K, Juvekar A, Sen S, Kurian N, Zingde S (2008) Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing ‘click’ chemistry: DNA-binding affinity and anticancer activity. Bioorg Med Chem Lett 18(4):1468–1473. https://doi.org/10.1016/j.bmcl.2007.12.063 CrossRefGoogle Scholar
- 25.Kumar A, Ahmad I, Chhikara BS, Tiwari R, Mandal D, Parang K (2011) Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities. Bioorg Med Chem Lett 21(5):1342–1346. https://doi.org/10.1016/j.bmcl.2011.01.047 CrossRefGoogle Scholar
- 27.Kamal A, Prabhakar S, Janaki Ramaiah M, Venkat Reddy P, Ratna Reddy C, Mallareddy A, Shankaraiah N, Lakshmi Narayan Reddy T, Pushpavalli SNCVL, Pal-Bhadra M (2011) Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers. Eur J Med Chem 46(9):3820–3831. https://doi.org/10.1016/j.ejmech.2011.05.050 CrossRefGoogle Scholar
- 30.Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, Masui T, Fujimoto K, Tamamura H, Hiramatsu K (2004) CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 3(1):29–37Google Scholar
- 33.Kamal A, Kumar GB, Vishnuvardhan MVPS, Shaik AB, Reddy VS, Mahesh R, Sayeeda IB, Kapure JS (2015) Synthesis of phenstatin/isocombretastatin–chalcone conjugates as potent tubulin polymerization inhibitors and mitochondrial apoptotic inducers. Org Biomol Chem 13(13):3963–3981. https://doi.org/10.1039/C4OB02606C CrossRefGoogle Scholar
- 34.Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, Chen H, Wu Z, Yang J, White SW, Miller DD, Li W (2018) Structural modification of the 3,4,5-Trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved Antiproliferative activities. J Med Chem 61(17):7877–7891. https://doi.org/10.1021/acs.jmedchem.8b00827 CrossRefGoogle Scholar